Aptose Biosciences (APTO) Gets a Buy Rating from Alliance Global Partners

Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aptose Biosciences (APTOResearch Report) today and set a price target of $8.00. The company’s shares closed last Wednesday at $1.22, close to its 52-week low of $1.00.

According to TipRanks.com, Cross is a 3-star analyst with an average return of 4.4% and a 36.6% success rate. Cross covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Syros Pharmaceuticals, and Aldeyra Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.72 average price target, representing a 548.7% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a C$12.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $7.20 and a one-year low of $1.00. Currently, Aptose Biosciences has an average volume of 420.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Read More on APTO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed